Results 61 to 70 of about 29,620 (204)

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer, Piotr Giedziun, Jacek Calik, Anna Wiela‐Hojeńska   +3 more
wiley   +1 more source

Plexiform Neurofibroma of Face: A Challenge for Plastic Surgeons

Journal of the Dow University of Health Sciences, 2009
Plexiform neurofibroma is a benign tumour of peripheral nerves and connective tissue. They developmost often in patients with neurofibromatosis type 1 (NF1) and often grow continuously.
Muhammad Ahmad, Saleem A. Malik
doaj   +4 more sources

Solitary Plexiform Neurofibroma of the Gingiva: Unique Presentation in the Oral Cavity [PDF]

Journal of Clinical and Diagnostic Research, 2013
Neurofibromas are benign tumours originating from the nerve sheath. Amongst the histological variants, plexiform types are considered exclusive. These are poorly circumscribed, locally invasive and may exhibit sarcomatous potential.
SURAMYA S., PRATIBHA SHASHIKUMAR, SHREESHYLA H.S., SHEELA KUMAR G.   +3 more
doaj   +1 more source

MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK

Oncogene, 2020
MicroRNAs (miRs) are small non-coding RNAs that can have large impacts on oncogenic pathways. Possible functions of dysregulated miRs have not been studied in neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNFs).
Youjin Na, Ashley Hall, Kwangmin Choi, Liang-liang Hu, J. Rose, Robert Coover, Adam Miller, R. Hennigan, E. Dombi, Mi-Ok Kim, Subbaya Subramanian, N. Ratner, Jianqiang Wu   +12 more
semanticscholar   +1 more source

Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano, Alexander Yelak, Walid Kaadan, Shlomo Caduri, Rivka Friedland, Orli Michaeli, Gad Dotan, Osnat Konen   +7 more
wiley   +1 more source

Neurodevelopmental and Psychiatric Studies in Children and Adolescents With Neurofibromatosis Type I: A Comprehensive Scoping Review

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, Volume 201, Issue 4, Page 257-269, June 2026.
ABSTRACT A comprehensive synthesis of the broad range of neurodevelopmental and psychiatric manifestations in NF1 is needed to identify knowledge gaps and future directions for NF1 research. In the following scoping review, we identify and summarize the scope of research that examines neurodevelopmental and psychiatric manifestations, both as ...
Meera Chopra, Tin‐Suet Joan Lee, Jacob Vorstman, Patricia Parkin, Louise Gallagher, Aneta Krakowski   +5 more
wiley   +1 more source

Giant plexiform neurofibroma with hemorrhage in cranio-maxillofacial region as depicted on CT and MRI

European Journal of Medical Research, 2010
Plexiform neurofibroma (PN) is a rare benign tumor and a special subtype of neurofibromatosis type 1 (NF1). Though the incidence is low, giant PN of the craniomaxillofacial region could result in severe hemifacial hypertrophy which is known as a typical ...
Feng Y, Yang Z, Chen T, Wang Q, Deng W
doaj   +1 more source

Surgery combined with embolization in the treatment of plexiform neurofibroma: Case report and literature review

JAAD Case Reports, 2020
Reinaldo Tovo Filho, MD, PhD, Francisco C esar Carnevale, MD, PhD, Tatiane Zago Curi, MD, Fernando Melhado Tovo, MD, Silmara da Costa Pereira Cestari, MD, PhD, Anna Paula Vaz de Oliveira Bomtempo, MD, Graziele Cristina Palâncio Morais, MD, Anaisa Raddo ...
R. Tovo Filho, F. Carnevale, Tatiane Zago Curi, Fernando Melhado Tovo, Silmara da Costa Pereira Cestari, Anna Paula Vaz de Oliveira Bomtempo, Graziele Cristina Palâncio Morais, Anaisa Raddo Venancio de Souza, R. Tovo, Luciana Zattar, Antônio Sérgio Zafred Marcelino, G. Cerri   +11 more
semanticscholar   +1 more source

Mediastinal mass in an tuberculosis-exposed 2-year old child with neurofibromatosis type 1 – TB or not TB?

Respiratory Medicine Case Reports, 2021
A toddler with neurofibromatosis type 1 (NF1) was evaluated for tuberculosis (TB) after exposure. Chest X-ray (CXR) revealed a mediastinal mass indicating lymphadenopathy. However, magnetic resonance imaging showed a large plexiform thoracic neurofibroma.
Renate Krüger, Cornelia Potratz, Pablo Hernáiz-Driever, Birgit Lala, Cornelia Feiterna-Sperling   +4 more
doaj   +1 more source

A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

BMC Cancer, 2019
Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the majority of PLGG have activation of the MAPK/ERK pathway.
S. Perreault, Valérie Larouche, U. Tabori, Cynthia Hawkin, S. Lippé, B. Ellezam, J. Décarie, Y. Théorêt, Marie-Élaine Métras, S. Sultan, Édith Cantin, Marie-Ève Routhier, M. Caru, G. Legault, E. Bouffet, L. Lafay-Cousin, J. Hukin, C. Erker, N. Jabado   +18 more
semanticscholar   +1 more source